PSC Category AN13 encompasses Health Research and Development (R&D) Services, Health Care Services, and Experimental Development. This category covers a wide range of medical and health-related research initiatives, including innovative diagnostic technologies, medical countermeasures, therapeutic development, and advanced healthcare solutions. The awards and opportunities span multiple domains such as biotechnology, medical device development, artificial intelligence in healthcare, and clinical research across various disease areas and medical technologies. The federal contract awards in this category demonstrate significant investment in cutting-edge medical research, with contract values ranging from approximately $13,000 to $338 million. Key funding agencies include the Office of the Assistant Secretary for Preparedness and Response (ASPR), National Institutes of Health (NIH), and the Defense Health Agency. Frequently awarded entities include academic institutions, biotechnology firms, and research organizations such as Battelle Memorial Institute, Tufts University, and various small biotechnology companies. Most awards are not set aside for specific business types, though some utilize small business designations. Performance locations are predominantly within the United States, with work primarily conducted at research institutions, medical centers, and corporate research facilities. The federal contract opportunities in this PSC category focus on groundbreaking medical research and technology development. Notable upcoming solicitations include the POSEIDON program for multi-cancer early detection, the PRECISE-AI initiative for maintaining AI performance in clinical settings, and the GLIDE program targeting lymphatic system interventions. These opportunities seek innovative solutions across diverse areas such as cancer screening, artificial intelligence in healthcare, lymphatic disease treatments, and advanced diagnostic technologies. Agencies like ARPA-H and NIH are actively seeking proposals from universities, research institutions, and biotechnology companies to develop transformative healthcare technologies and medical research platforms.
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Last Date To Order (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
36C10X22D0026 | Longview International Technology Solutions, Inc. | $650.0m | 9/30/22 | 9/29/27 | 6/30/23 | |
HHSO100201100046C | Meso Scale Diagnostics LLC | $2.8m | 9/21/11 | 9/20/18 | 9/20/18 | |
75A50122D00017 | Battelle Memorial Institute | $100.0m | 9/30/22 | 9/29/27 | 7/12/24 | |
75A50119D00015 | Emory University | $634.5k | 2/1/19 | 6/30/21 | 6/29/21 | |
36C10X22D0020 | Guidehouse Inc. | $650.0m | 9/30/22 | 9/29/27 | 6/30/23 |
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Completion Date (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
Definitive Contract W81XWH22C0085 | Design Interactive, Inc. | $3.8m | 9/23/22 | 10/22/25 | 9/21/22 | |
Delivery Order F3361582C0618-HR010198404C0078F3361582C0618 |
--
| TSI Incorporated | $0 | 4/15/84 | Not listed | 4/15/84 |
Definitive Contract 75A50121C00044 | Enalare Therapeutics Inc. | $749.0k | 4/26/21 | 11/30/22 | 7/21/22 | |
Definitive Contract 00266200305D266030023 | Protein Sciences Corp | $26.6k | 5/15/03 | 11/30/12 | 12/13/18 | |
Purchase Order VA25116P0183 | Jackson Laboratory | $17.7k | 12/1/15 | 6/30/16 | 1/25/17 |
A Portfolio Platform of GovExec © 2025